title: Cancer vaccines: are we there yet?
abstract: For nearly two decades there has been an abundance of research and clinical development programs underway to develop active specific immunotherapies, to educate the patient's immune response, specifically the T-cell immunity and memory, to recognize and destroy tumor cells by cell-mediated cellular toxicity. While many of these technology platforms achieved promising results in preclinical and clinical phase I and II clinical trials, essentially all but one have failed to achieve FDA market approval as a therapeutic drug product.
authors.affiliation: Vaccinogen Inc.,Frederick, MD USA. mghannajr@vaccinogeninc.com
authors.forename: Michael G
authors.initials: MG
authors.lastname: Hanna
mesh_terms: D000951:Antigens, Neoplasm / Q000235:genetics / Q000276:immunology*; D019496:Cancer Vaccines / Q000235:genetics / Q000276:immunology* / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D055808:Drug Discovery / Q000639:trends*; D006801:Humans; D009369:Neoplasms / Q000628:therapy*
chemical_list: D000951:Antigens, Neoplasm; D019496:Cancer Vaccines